<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907918</url>
  </required_header>
  <id_info>
    <org_study_id>201610019</org_study_id>
    <nct_id>NCT02907918</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer</brief_title>
  <acronym>PALTAN</acronym>
  <official_title>A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to influence estrogen receptor (ER) signaling by combining
      endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal
      growth factor receptor 2 (HER2)+ early stage breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR) rate</measure>
    <time_frame>Completion of 4 cycles of treatment (approximately 16 weeks)</time_frame>
    <description>A pathologic complete response (pCR) is defined as no histology evidence of invasive tumor cells in the surgical breast specimen and sentinel or axillary lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of palbociclib in combination with neoadjuvant letrozole and trastuzumab as measured by frequency of adverse events</measure>
    <time_frame>30 days after completion of neoadjuvant therapy (approximately 21 weeks)</time_frame>
    <description>-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes as measured by NCI PRO-CTCAE</measure>
    <time_frame>Completion of treatment (approximately 16 weeks)</time_frame>
    <description>10 item questionnaire with 2 questions per item
The first part of the question has answers ranging from None to Very Severe.
The second part of the question has answers ranging from Not at All to Very Much
PRO-CTCAE responses are scored from 0 to 4, and there are no standardized scoring rules yet established for how to combine attributes into a single score or how best to analyse PRO-CTCAE data longitudinally.
PRO-CTCAE scores for each attribute (frequency, severity and/or interference) will be presented descriptively</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cancer of Breast</condition>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles
Definitive surgery within 3-5 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
    <other_name>Femara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery.</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
    <other_name>Herceptin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast surgery</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Research tumor biopsy</intervention_name>
    <description>Baseline, cycle 1 day 15, and surgery</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Research bone marrow (OPTIONAL)</intervention_name>
    <description>Baseline and surgery</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Research blood sample</intervention_name>
    <description>Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Research blood for germline DNA</intervention_name>
    <description>Baseline</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood for detection of circulating tumor cells</intervention_name>
    <description>Baseline</description>
    <arm_group_label>Palbociclib + letrozole + trastuzumab +/- goserelin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed clinical stage II or III ER+/HER2+ breast cancer with complete
             surgical excision of the breast cancer after neoadjuvant therapy as the treatment
             goal.

          -  Tumor size at least 2 cm in one dimension by clinical or radiographic exam (World
             Health Organization (WHO) criteria). Patients with histologically confirmed palpable
             lymph nodes may be enrolled regardless of breast tumor size.

          -  At least 18 years of age.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

          -  Normal bone marrow and organ function as defined below:

               -  Leukocytes ≥ 3,000/mcL

               -  Absolute neutrophil count ≥ 1,500/mcl

               -  Platelets ≥ 100,000/mcl

               -  Total bilirubin ≤ institutional upper limit of normal (IULN)

               -  AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN

          -  Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m^2 for patients with
             creatinine levels above institutional normal

          -  Left ventricular ejection fraction (LVEF) ≥ 50% by transthoracic echocardiogram or
             multigated acquisition scan (MUGA)

          -  Baseline corrected QT interval (QTcF) &lt; 480 ms

          -  Women of childbearing potential must agree to undergo pregnancy testing within 14 days
             of study entry and agree to use adequate contraception (barrier method of birth
             control, abstinence, not hormonal) prior to study entry and for the duration of study
             participation as well as chemical ovarian suppression with goserelin. Should a woman
             become pregnant or suspect she is pregnant while participating in this study, she must
             inform her treating physician immediately.

          -  Ability to understand and willingness to sign an IRB approved written informed consent
             document (or that of legally authorized representative, if applicable).

        Exclusion Criteria:

          -  Prior systemic therapy for indexed breast cancer.

          -  Indeterminate or negative HER2 status.

          -  Inflammatory breast cancer.

          -  A history of other malignancy ≤ 5 years from diagnosis of indexed BC with the
             exception of basal cell or squamous cell carcinoma of the skin treated with local
             resection only or carcinoma in situ of the cervix.

          -  Currently receiving any other investigational agents or received any within the past
             28 days.

          -  Know to be HIV positive.

          -  Known hepatitis B or C infection.

          -  A history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase
             inhibitor, any other monoclonal antibody, or other agents used in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
             arrhythmia.

          -  Current use or anticipated need for food or drugs that are known strong CYP3A4
             inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole,
             posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir,
             ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone,
             diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids,
             progesterone, rifampin, phenobarbital, St. John's wort).

          -  Any condition that impairs the ability to swallow or absorb oral medication (e.g.,
             gastrointestinal tract disease resulting in an inability to take oral medication or a
             requirement for IV alimentation, prior surgical procedures affective absorption).

          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative
             pregnancy test within 14 days of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Foluso O Ademuyiwa, M.D, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Foluso O Ademuyiwa, M.D., MPH</last_name>
    <phone>(314) 454-8313</phone>
    <email>bisiademuyiwa@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy D Miller, M.D.</last_name>
      <phone>317-948-3885</phone>
    </contact>
    <investigator>
      <last_name>Kathy D Miller, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Physicians</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Foluso O Ademuyiwa, M.D., MPH</last_name>
      <phone>314-454-8313</phone>
      <email>bisiademuyiwa@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Foluso O Ademuyiwa, M.D., MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia X Ma, M.D, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca L Aft, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Bose, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Cherian, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Cyr, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Eberlein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Frith, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Will Gillanders, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonel Hernandez-Aya, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Oppelt, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haesong Park, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caron Rigden, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Souzan Sanati, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsey Peterson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>R. Reid Townsend, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ellis Levine, M.D.</last_name>
      <phone>716-845-2900</phone>
    </contact>
    <investigator>
      <last_name>Ellis Levine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doctor's Hospital of Laredo</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Unzeitig, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

